221 related articles for article (PubMed ID: 2821862)
1. Gallium nitrate for treatment of refractory hypercalcemia from parathyroid carcinoma.
Warrell RP; Issacs M; Alcock NW; Bockman RS
Ann Intern Med; 1987 Nov; 107(5):683-6. PubMed ID: 2821862
[TBL] [Abstract][Full Text] [Related]
2. Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia.
Warrell RP; Bockman RS; Coonley CJ; Isaacs M; Staszewski H
J Clin Invest; 1984 May; 73(5):1487-90. PubMed ID: 6715548
[TBL] [Abstract][Full Text] [Related]
3. Therapy of hypercalcemia due to parathyroid carcinoma with intravenous dichloromethylene diphosphonate.
Shane E; Jacobs TP; Siris ES; Steinberg SF; Stoddart K; Canfield RE; Bilezikian JP
Am J Med; 1982 Jun; 72(6):939-44. PubMed ID: 6211978
[TBL] [Abstract][Full Text] [Related]
4. Gallium nitrate inhibits accelerated bone turnover in patients with bone metastases.
Warrell RP; Alcock NW; Bockman RS
J Clin Oncol; 1987 Feb; 5(2):292-8. PubMed ID: 3806170
[TBL] [Abstract][Full Text] [Related]
5. Mithramycin treatment of intractable hypercalcemia due to parathyroid carcinoma.
Singer FR; Neer RM; Murray TM; Keutmann HT; Deftos LJ; Potts JT
N Engl J Med; 1970 Sep; 283(12):634-6. PubMed ID: 5450637
[No Abstract] [Full Text] [Related]
6. Calcitonin treatment of hypercalcemia due to parathyroid carcinoma. Synergistic effect of prednisone on long-term treatment of hypercalcemia.
Au WY
Arch Intern Med; 1975 Dec; 135(12):1594-7. PubMed ID: 128332
[No Abstract] [Full Text] [Related]
7. Treatment of cancer-related hypercalcemia: the role of gallium nitrate.
Leyland-Jones B
Semin Oncol; 2003 Apr; 30(2 Suppl 5):13-9. PubMed ID: 12776255
[TBL] [Abstract][Full Text] [Related]
8. Effect of gallium nitrate on tamoxifen induced hypercalcemia in rats bearing mammary tumor.
Arumugam G; Shanthi P; Sachdanandam P
Exp Oncol; 2006 Jun; 28(2):141-5. PubMed ID: 16837906
[TBL] [Abstract][Full Text] [Related]
9. Hypercalcemia induced with the plasma levels of parathyroid hormone-related peptide in multiple myeloma.
Shionoiri A; Horiuchi T; Onouchi T; Tsutsumi H; Ohta M; Hosoi T; Ito H; Orimo H
Intern Med; 2000 Oct; 39(10):810-3. PubMed ID: 11030205
[TBL] [Abstract][Full Text] [Related]
10. First Japanese patient treated with parathyroid hormone peptide immunization for refractory hypercalcemia caused by metastatic parathyroid carcinoma.
Horie I; Ando T; Inokuchi N; Mihara Y; Miura S; Imaizumi M; Usa T; Kinoshita N; Sekine I; Kamihara S; Eguchi K
Endocr J; 2010; 57(4):287-92. PubMed ID: 20051648
[TBL] [Abstract][Full Text] [Related]
11. [Tumoral hypercalcemia: physiopathology and treatment].
Rizzoli R; Jung A; Bonjour JP
Schweiz Med Wochenschr; 1985 Mar; 115(10):326-32. PubMed ID: 3157214
[TBL] [Abstract][Full Text] [Related]
12. Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent.
Collins MT; Skarulis MC; Bilezikian JP; Silverberg SJ; Spiegel AM; Marx SJ
J Clin Endocrinol Metab; 1998 Apr; 83(4):1083-8. PubMed ID: 9543122
[TBL] [Abstract][Full Text] [Related]
13. Treating cancer-related hypercalcemia with gallium nitrate.
Leyland-Jones B
J Support Oncol; 2004; 2(6):509-16. PubMed ID: 15605917
[TBL] [Abstract][Full Text] [Related]
14. Effects of gallium nitrate in nude mice bearing a canine adenocarcinoma (CAC-8) model of humoral hypercalcemia of malignancy.
Merryman JI; Capen CC; Rosol TJ
J Bone Miner Res; 1994 May; 9(5):725-32. PubMed ID: 8053402
[TBL] [Abstract][Full Text] [Related]
15. Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers.
Horwitz MJ; Tedesco MB; Sereika SM; Hollis BW; Garcia-Ocaña A; Stewart AF
J Clin Endocrinol Metab; 2003 Apr; 88(4):1603-9. PubMed ID: 12679445
[TBL] [Abstract][Full Text] [Related]
16. Suppression of parathyroid secretion after administration of WR-2721 in a patient with parathyroid carcinoma.
Hirschel-Scholz S; Jung A; Fischer JA; Trechsel U; Bonjour JP
Clin Endocrinol (Oxf); 1985 Sep; 23(3):313-8. PubMed ID: 3000652
[TBL] [Abstract][Full Text] [Related]
17. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy.
Rizzoli R; Thiébaud D; Bundred N; Pecherstorfer M; Herrmann Z; Huss HJ; Rückert F; Manegold C; Tubiana-Hulin M; Steinhauer EU; Degardin M; Thürlimann B; Clemens MR; Eghbali H; Body JJ
J Clin Endocrinol Metab; 1999 Oct; 84(10):3545-50. PubMed ID: 10522993
[TBL] [Abstract][Full Text] [Related]
18. The emerging role of denosumab in the long-term management of parathyroid carcinoma-related refractory hypercalcemia.
Fountas A; Andrikoula M; Giotaki Z; Limniati C; Tsakiridou E; Tigas S; Tsatsoulis A
Endocr Pract; 2015 May; 21(5):468-73. PubMed ID: 25667369
[TBL] [Abstract][Full Text] [Related]
19. The hypercalciurias. Causes, parathyroid functions, and diagnostic criteria.
Pak CY; Oata M; Lawrence EC; Snyder W
J Clin Invest; 1974 Aug; 54(2):387-400. PubMed ID: 4367891
[TBL] [Abstract][Full Text] [Related]
20. Increased prevalence of primary hyperparathyroidism in treated breast cancer.
Fierabracci P; Pinchera A; Miccoli P; Conte PF; Vignali E; Zaccagnini M; Marcocci C; Giani C
J Endocrinol Invest; 2001 May; 24(5):315-20. PubMed ID: 11407650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
